Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Held by: IWM VTI IWN VXF IBB FESM SCHA DWAS VFMO VTWO

Index	RUT	P/E	-	EPS (ttm)	-2.11	Insider Own	31.43%	Shs Outstand	35.85M	Perf Week	-5.60%
Market Cap	817.10M	Forward P/E	-	EPS next Y	-2.85	Insider Trans	-2.68%	Shs Float	28.63M	Perf Month	-14.62%
Enterprise Value	538.45M	PEG	-	EPS next Q	-0.76	Inst Own	31.09%	Short Float	3.18%	Perf Quarter	144.32%
Income	-75.79M	P/S	138.02	EPS this Y	65.51%	Inst Trans	1.02%	Short Ratio	1.45	Perf Half Y	338.79%
Sales	5.92M	P/B	2.53	EPS next Y	-24.47%	ROA	-23.59%	Short Interest	0.91M	Perf YTD	47.92%
Book/sh	7.74	P/C	2.86	EPS next 5Y	25.86%	ROE	-25.64%	52W High	24.00 -18.46%	Perf Year	332.96%
Cash/sh	6.84	P/FCF	-	EPS past 3/5Y	-30.62% -	ROIC	-27.08%	52W Low	2.88 579.51%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	96.77%	Volatility	7.24% 7.48%	Perf 5Y	-
Dividend TTM	-	EV/Sales	90.95	EPS Y/Y TTM	-1.89%	Oper. Margin	-1516.29%	ATR (14)	1.45	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.87	Sales Y/Y TTM	-	Profit Margin	-1280.90%	RSI (14)	55.84	Recom	2.20
Dividend Gr. 3/5Y	- -	Current Ratio	11.87	EPS Q/Q	17.81%	SMA20	-1.12%	Beta	1.37	Target Price	30.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	20.13%	Rel Volume	2.18	Prev Close	19.94
Employees	64	LT Debt/Eq	0.01	Earnings	Nov 06 AMC	SMA200	143.94%	Avg Volume	625.65K	Price	19.57
IPO	Sep 26, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.04% 164.18%	Trades		Volume	1,366,039	Change	-1.86%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-26	Initiated	Piper Sandler	Overweight	$73
Dec-05-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$12
Oct-22-25	Upgrade	Citigroup	Neutral → Buy	$10
Feb-28-25	Initiated	William Blair	Mkt Perform
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight	$40 → $5
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$42 → $7
Dec-09-24	Downgrade	Citigroup	Buy → Neutral	$45 → $7
Oct-21-24	Initiated	Morgan Stanley	Overweight	$40
Oct-21-24	Initiated	Jefferies	Buy	$42
Oct-21-24	Initiated	Citigroup	Buy	$45

Jan-29-26 03:00AM	Eli Lilly, BioAge chase NLRP3 inhibitors with pipeline in a pill potential (Pharma Voice)
Jan-21-26 10:30PM	BioAge Announces Pricing of Upsized $115.0 Million Public Offering (GlobeNewswire) -5.63% -6.06%
Jan-20-26 04:01PM	BioAge Announces Proposed Public Offering (GlobeNewswire) +5.75%
09:00AM	BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 (GlobeNewswire)
Jan-12-26 01:06PM	BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio (Investor's Business Daily) +27.23%
09:00AM	Loading…
09:00AM	BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk (GlobeNewswire)
Dec-13-25 10:35AM	2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole (Motley Fool)
Dec-04-25 09:00AM	BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor (GlobeNewswire) +13.88%
Nov-25-25 04:30PM	BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-07-25 09:00AM	BioAge Labs to Present at Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-06-25 04:45PM	BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-05-25 07:45AM	Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy (Motley Fool)
Oct-29-25 06:15AM	Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? (Motley Fool)
Oct-26-25 06:33PM	BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? (Motley Fool)
Oct-23-25 07:36AM	Ventyx shares soar after study suggests cardiovascular benefits for experimental drug (BioPharma Dive) +31.40%
04:30PM	Loading…
Aug-20-25 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 07:36AM	BioAge commences dosing in trial of obesity treatment candidate BGE-102 (Clinical Trials Arena)
Aug-15-25 09:00AM	BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor (GlobeNewswire)
Aug-06-25 04:30PM	BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-29-25 10:23AM	BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery (Insider Monkey)
Jun-21-25 06:00PM	BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions (GlobeNewswire)
Jun-17-25 09:00AM	BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank (GlobeNewswire)
Jun-03-25 09:00AM	BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates (GlobeNewswire)
May-30-25 09:05AM	BioAge Labs completes IND-enabling studies for BGE-102 (TipRanks)
May-29-25 11:18PM	BioAge Labs, Inc. (BIOA)'s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 (Insider Monkey)
09:00AM	BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic (GlobeNewswire)
May-27-25 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
May-06-25 04:30PM	BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-21-25 01:02PM	BioAge Labs, Inc. (BIOA): A Bull Case Theory (Insider Monkey)
Mar-22-25 11:00AM	Investors To Focus On PCE Price Index Print As Cintas, Lululemon To Report Earnings (SeekingAlpha)
04:30PM	Loading…
Mar-20-25 04:30PM	BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 (GlobeNewswire)
Mar-17-25 01:54PM	BioArctic receives Orphan Drug Designation for exidavnemab the US (PR Newswire)
Mar-04-25 05:07AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
Feb-20-25 04:30PM	BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference (GlobeNewswire)
10:36AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
Feb-16-25 07:18AM	BIOA COURT NEWS: BioAge Labs has been Sued for Securities Violations; Contact BFA Law by March 10 if You Lost Money (NASDAQ:BIOA) (GlobeNewswire)
Feb-14-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire) +5.97%
Feb-13-25 08:42AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Feb-07-25 05:45AM	BioAge Labs, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-30-25 09:01AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Jan-29-25 05:39AM	BioAge drops obesity drug; Akero, 89bio cash in on MASH data (BioPharma Dive) -6.40%
Jan-28-25 07:27PM	Kessler Topaz Meltzer & Check, LLP Encourages BioAge Labs, Inc. Investors with Losses to Contact the Firm (PR Newswire)
09:00AM	BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs (GlobeNewswire)
Jan-24-25 05:45AM	Shareholders of BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-22-25 03:00AM	After an obesity stumble, BioAge reconnects with its longevity pipeline (Pharma Voice)
Jan-21-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-18-25 03:07AM	BIOAGE LABS (BIOA) Investors are Notified the Company has been Sued and are Urged to Contact BFA Law by March 10 (Newsfile)
Jan-06-25 09:00PM	Bragar Eagel and Squire, P.C. Is Investigating Franklin, MediaAlpha, e.l.f. Beauty, and BioAge and Encourages Investors to Contact the Firm (GlobeNewswire) -7.39%
Jan-03-25 12:51PM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (PR Newswire)
Jan-02-25 09:35AM	BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-01-25 05:00AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-27-24 11:32AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -6.46%
09:18AM	BioAge Labs, Inc. (BIOA): A Bull Case Theory (Insider Monkey)
Dec-26-24 07:23AM	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against BioAge Labs, Inc. (BIOA) (Newsfile)
Dec-25-24 07:04AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-23-24 10:19AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-19-24 01:15PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) +20.23%
05:46AM	BioAge and Novartis seek drug targets for ageing-related diseases (Pharmaceutical Technology)
Dec-18-24 09:00AM	BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions (GlobeNewswire)
Dec-16-24 04:20PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
03:00AM	3 closely watched drugs that failed in the clinic (Pharma Voice)
Dec-13-24 10:31AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile) -6.75%
Dec-12-24 06:34PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-09-24 07:51PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -76.85%
09:28AM	BioAge halts ongoing Phase II trial of obesity drug due to liver concerns (Clinical Trials Arena)
07:41AM	Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns (Benzinga)
Dec-07-24 06:34AM	BioAge shares tumble after decision to halt obesity drug study (BioPharma Dive)
Dec-06-24 04:35PM	BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity (GlobeNewswire) +9.36% -76.85%
Dec-05-24 04:30PM	BioAge Labs to Present at Goldman Sachs Year-Ahead Catalyst Clinic (GlobeNewswire)
Dec-04-24 04:47PM	Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now? (Insider Monkey)
Nov-21-24 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 11:01PM	BioAge Labs Reports Strong Q3 2024 Achievements (TipRanks) -11.78%
Nov-07-24 04:30PM	BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -10.11% +7.61%
Nov-04-24 09:00AM	BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 (GlobeNewswire)
Oct-24-24 09:00AM	BioAge Labs to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 10:53AM	Wall Street analysts initiate coverage of BioAge Labs (Investing.com) +8.26%
Oct-17-24 09:45AM	Prediction: These 2 Stocks Could Soar in 2025 (Motley Fool)
Oct-12-24 02:31PM	Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock (Motley Fool)
Oct-07-24 09:10PM	RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc (GuruFocus.com)
Oct-05-24 07:15AM	3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October (Motley Fool)
Oct-03-24 09:05AM	This IPO Biotech Stock Could Be the Next Eli Lilly (Motley Fool) +5.73%
Oct-01-24 04:30PM	BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement (GlobeNewswire)
Sep-26-24 04:08PM	BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO (Investor's Business Daily)
02:36PM	A weight loss drug developer's stock soars after a $198 million IPO (Quartz)
08:25AM	BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq (FastCompany)
Sep-25-24 08:00PM	BioAge Labs Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
04:13PM	BioAge prices $198M IPO, validating pivot to obesity drug research (BioPharma Dive)
11:27AM	A weight loss drug maker is aiming for a big IPO (Quartz)

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RUBIN PAUL D	Chief Medical Officer	Feb 02 '26	Option Exercise	4.77	7,433	35,470	7,433	Feb 03 04:26 PM
RUBIN PAUL D	Chief Medical Officer	Feb 02 '26	Sale	18.75	7,433	139,369	0	Feb 03 04:26 PM
GOLDSTEIN DOV A MD	Chief Financial Officer	Feb 01 '26	Option Exercise	4.38	3,541	15,510	29,491	Feb 03 04:23 PM
RUBIN PAUL D	Officer	Feb 02 '26	Proposed Sale	18.75	7,433	139,369		Feb 02 09:43 AM
GOLDSTEIN DOV A MD	Chief Financial Officer	Jan 16 '26	Option Exercise	4.38	3,542	15,514	25,950	Jan 21 04:20 PM
GOLDSTEIN DOV A MD	Chief Financial Officer	Jan 13 '26	Option Exercise	8.39	27,000	226,530	49,408	Jan 15 04:22 PM
GOLDSTEIN DOV A MD	Chief Financial Officer	Jan 13 '26	Sale	19.70	27,000	531,828	22,408	Jan 15 04:22 PM
Fortney Kristen	Chief Executive Officer	Jan 13 '26	Sale	18.12	233,107	4,223,036	976,949	Jan 15 04:20 PM
Fortney Kristen	10% Owner	Jan 13 '26	Proposed Sale	18.00	233,107	4,195,926		Jan 13 04:36 PM
GOLDSTEIN DOV A MD	Officer	Jan 13 '26	Proposed Sale	19.70	27,000	531,828		Jan 13 04:16 PM
RUBIN PAUL D	Chief Medical Officer	Jan 02 '26	Option Exercise	4.77	7,433	35,470	7,433	Jan 06 04:24 PM
RUBIN PAUL D	Chief Medical Officer	Jan 02 '26	Sale	12.85	7,433	95,490	0	Jan 06 04:24 PM
RUBIN PAUL D	Officer	Jan 02 '26	Proposed Sale	13.41	7,433	99,677		Jan 02 12:56 PM
RUBIN PAUL D	Chief Medical Officer	Dec 09 '25	Option Exercise	6.57	18,000	118,260	18,000	Dec 11 04:21 PM
RUBIN PAUL D	Chief Medical Officer	Dec 09 '25	Sale	12.00	18,000	216,000	0	Dec 11 04:21 PM
RUBIN PAUL D	Officer	Dec 09 '25	Proposed Sale	12.00	18,000	216,000		Dec 09 11:23 AM
RUBIN PAUL D	Chief Medical Officer	Dec 04 '25	Option Exercise	4.11	68,897	283,167	68,897	Dec 05 06:20 PM
RUBIN PAUL D	Chief Medical Officer	Dec 04 '25	Sale	10.19	68,897	701,909	0	Dec 05 06:20 PM
RUBIN PAUL D	Officer	Dec 04 '25	Proposed Sale	10.19	68,897	701,912		Dec 04 04:30 PM

Open in Screener

ALXO

Alx Oncology Holdings Inc

Feb 13 • 04:00PM ET

2.21

-0.19 -8.11 %

Healthcare • Biotechnology • USA • NASD

ALXO Alx Oncology Holdings Inc daily Stock Chart

Peers: IOVA KPTI SRRK XNCR TVRD AFMD TGTX BHVN ZLAB BPMC

| Held by: VTI VXF VHT BTEC AVSC AVTM

Index	-	P/E	-	EPS (ttm)	-2.03	Insider Own	47.22%	Shs Outstand	53.58M	Perf Week	7.80%
Market Cap	289.95M	Forward P/E	-	EPS next Y	-0.88	Insider Trans	5.71%	Shs Float	28.62M	Perf Month	66.17%
Enterprise Value	244.93M	PEG	-	EPS next Q	-0.36	Inst Own	59.81%	Short Float	3.97%	Perf Quarter	72.66%
Income	-108.01M	P/S	-	EPS this Y	29.36%	Inst Trans	-5.18%	Short Ratio	2.83	Perf Half Y	237.40%
Sales	0.00M	P/B	2.64	EPS next Y	51.71%	ROA	-80.47%	Short Interest	1.14M	Perf YTD	95.58%
Book/sh	0.84	P/C	4.78	EPS next 5Y	35.57%	ROE	-118.95%	52W High	2.62 -15.65%	Perf Year	104.63%
Cash/sh	0.46	P/FCF	-	EPS past 3/5Y	-7.67% -32.29%	ROIC	-199.54%	52W Low	0.40 447.03%	Perf 3Y	-72.78%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	16.97% 14.24%	Perf 5Y	-97.30%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	31.98%	Oper. Margin	-	ATR (14)	0.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.40	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	63.19	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	2.40	EPS Q/Q	29.07%	SMA20	22.29%	Beta	0.42	Target Price	3.33
Payout	-	Debt/Eq	0.35	Sales Q/Q	-	SMA50	44.28%	Rel Volume	1.22	Prev Close	2.40
Employees	80	LT Debt/Eq	0.21	Earnings	Nov 07 BMO	SMA200	99.55%	Avg Volume	400.97K	Price	2.21
IPO	Jul 17, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-11.81% -	Trades		Volume	489,564	Change	-8.11%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-13-25	Initiated	Jefferies	Buy	$4
Mar-06-25	Upgrade	Jefferies	Hold → Buy	$2 → $3
Dec-19-24	Downgrade	Jefferies	Buy → Hold	$12 → $2
Mar-08-24	Downgrade	Stifel	Buy → Hold	$10 → $14
Dec-08-23	Upgrade	Jefferies	Hold → Buy	$8 → $18
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$65 → $25
Sep-30-21	Initiated	Stifel	Buy	$106
May-05-21	Resumed	Credit Suisse	Outperform	$98
Apr-26-21	Resumed	Credit Suisse	Outperform	$98
Apr-06-21	Initiated	UBS	Buy
Feb-10-21	Initiated	H.C. Wainwright	Buy	$100
Aug-11-20	Initiated	Piper Sandler	Overweight	$55
Aug-11-20	Initiated	Jefferies	Buy	$50
Aug-11-20	Initiated	Credit Suisse	Outperform	$53
Aug-11-20	Initiated	Cantor Fitzgerald	Overweight	$64

Show Previous Ratings

Feb-09-26 09:40AM	Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? (Zacks) +14.15%
Jan-30-26 08:30AM	ALX Oncology Announces Pricing of Underwritten Offering (GlobeNewswire) +10.83%
08:15AM	New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer (GlobeNewswire)
Jan-15-26 05:17PM	ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference (MarketBeat) -9.02%
Jan-08-26 11:00AM	ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +5.08%
08:30AM	Loading…
08:30AM	ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 (GlobeNewswire)
Dec-07-25 08:00AM	ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting (GlobeNewswire)
Nov-18-25 11:00AM	ALX Oncology to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-08-25 02:05AM	ALX Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Highlights: Promising Clinical Advances ... (GuruFocus.com)
Nov-07-25 08:15AM	ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +16.95%
Oct-30-25 08:30AM	ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting (GlobeNewswire)
Oct-23-25 12:30PM	ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference (GlobeNewswire) +8.70%
Oct-14-25 09:40AM	Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year? (Zacks) -8.11%
Oct-03-25 09:05AM	ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) +14.14%
Sep-12-25 08:30AM	ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer (GlobeNewswire) -10.17%
12:00PM	Loading…
Aug-29-25 12:00PM	ALX Oncology to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-19-25 08:00AM	ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors (GlobeNewswire) -8.37%
Aug-13-25 03:13AM	ALX Oncology Holdings Inc (ALXO) Q2 2025 Earnings Call Highlights: Promising Trial Results and ... (GuruFocus.com) +7.40%
Aug-12-25 04:05PM	ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-25 08:00AM	ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire) +12.68%
May-30-25 08:00AM	ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference (GlobeNewswire)
May-20-25 08:00AM	ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event (GlobeNewswire)
May-13-25 08:00AM	ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 (GlobeNewswire) +10.52%
May-08-25 08:30AM	ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-25 08:00AM	ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-28-25 07:51AM	ALX Oncologys CD47-blocker and Keytruda combo fails in two Phase II trials (Clinical Trials Arena)
Apr-25-25 01:10PM	ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma (GlobeNewswire) -9.87%
09:00AM	ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints (GlobeNewswire)
Apr-07-25 08:00AM	ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate (GlobeNewswire)
Mar-20-25 09:55AM	ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
07:33AM	Loading…
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
Mar-07-25 01:27PM	Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday (Insider Monkey) -19.08%
Mar-06-25 04:01PM	ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +25.96%
Mar-05-25 08:00AM	ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event (GlobeNewswire)
Feb-27-25 08:00AM	ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 (GlobeNewswire)
Feb-18-25 08:00AM	ALX Oncology to Host Virtual R&D Day on March 5, 2025 (GlobeNewswire) +7.27%
Jan-23-25 02:44PM	ALX Oncology Shares Drop 15% Following Positive Phase 2 (GuruFocus.com) -9.44%
08:00AM	ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer (GlobeNewswire)
Jan-22-25 04:01PM	ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules (GlobeNewswire) +9.09%
09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
08:00AM	ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors (GlobeNewswire)
Jan-21-25 05:00PM	ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI (GlobeNewswire) -5.17%
Jan-07-25 09:40AM	Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? (Zacks)
08:00AM	ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-24 08:57AM	Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold' (Investing.com) -19.57%
Dec-18-24 08:00AM	ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Dec-12-24 08:00AM	ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 (GlobeNewswire) -5.96%
Dec-10-24 09:00AM	ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer (GlobeNewswire) -8.14%
Nov-26-24 08:00AM	ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-21-24 09:35AM	ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +6.61%
Nov-14-24 08:00AM	ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-07-24 04:00PM	ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-24 08:00AM	ALX Oncology Announces November Investor Conference Participation (GlobeNewswire)
Nov-01-24 05:30PM	ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 (GlobeNewswire)
Oct-10-24 07:04PM	Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc (GuruFocus.com) -11.11% +6.94%
Sep-09-24 08:00AM	ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) +9.95%
Sep-04-24 08:00AM	ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi (GlobeNewswire)
Aug-08-24 04:05PM	ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-06-24 04:01PM	ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors (GlobeNewswire) -6.55%
Aug-01-24 09:05AM	Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients (Benzinga) -41.67%
06:52AM	ALX Oncologys evorpacept shows potential in Phase II gastric cancer trial (Clinical Trials Arena)
Jul-31-24 04:01PM	ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer (GlobeNewswire) -11.93%
05:30AM	ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Jun-17-24 11:00AM	Insider Buying: CFO Peter Garcia Acquires Shares of ALX Oncology Holdings Inc (ALXO) (GuruFocus.com) -8.32%
Jun-03-24 09:35AM	Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround (Zacks) -15.71%
Jun-02-24 10:00AM	ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer (GlobeNewswire)
May-29-24 09:00AM	ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference (GlobeNewswire) -10.91%
May-16-24 02:54AM	Insider Sale: Chief Medical Officer of ALX Oncology Holdings Inc (ALXO) Sells Shares (GuruFocus.com)
May-14-24 09:55AM	Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet (Zacks)
May-10-24 02:21PM	ALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ... (GuruFocus.com)
May-09-24 10:57PM	ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024 (InvestorPlace)
04:00PM	ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 05:38PM	Alx Oncology Holdings Insider Sold Shares Worth $318,334, According to a Recent SEC Filing (MT Newswires) -5.41%
May-07-24 09:00AM	ALX Oncology Appoints Allison Dillon as Chief Business Officer (GlobeNewswire) +11.28%
Apr-30-24 09:00AM	ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer (GlobeNewswire)
Apr-24-24 10:00AM	ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-11-24 09:30AM	ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study (Zacks) +11.04%
Apr-09-24 05:30PM	ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma ( R/R B-NHL ) (GlobeNewswire)
Apr-06-24 01:33AM	ALX Oncology Holdings Inc (ALXO) Insider Sells Shares (GuruFocus.com)
Mar-08-24 03:48PM	ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer (Benzinga) -6.34%
Mar-07-24 10:53PM	ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q4 2023 (InvestorPlace) +9.95%
10:41PM	ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending (GuruFocus.com)
04:03PM	ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-24 04:30PM	ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting (GlobeNewswire)
Jan-03-24 08:00AM	ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-23 04:21PM	7 Small-Cap Stocks That Wall Street Loves for Good Reason (InvestorPlace) +18.04%
Nov-13-23 04:47PM	ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate Developments (GuruFocus.com) +8.08%
04:05PM	ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-23 04:05PM	ALX Oncology Announces November Investor Conference Participation (GlobeNewswire) +6.35%
Oct-10-23 04:05PM	ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +16.24%
Oct-06-23 04:59AM	The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna (Zacks) +27.38%
Oct-05-23 10:58AM	Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More (Zacks)
08:00AM	ALX Oncology Announces Pricing of Public Offering (GlobeNewswire)
Oct-04-23 04:10PM	ALX Oncology Announces Proposed Public Offering (GlobeNewswire) -15.05%
11:39AM	ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data (Zacks)
Oct-03-23 11:15AM	Why ALX Oncology Stock Is Skyrocketing Today (Motley Fool) +56.13%
09:36AM	Midday movers: McCormick Airbnb, Point Biopharma and more (Investing.com)
06:00AM	ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Oct-02-23 04:05PM	ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Sep-06-23 08:00AM	ALX Oncology Realigns Executive Leadership Team (GlobeNewswire) +6.37%

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GOODMAN COREY S	Director	Feb 02 '26	Buy	1.57	3,184,713	4,999,999	8,453,038	Feb 04 04:15 PM
Pinto Shelly	SVP, FINANCE AND CAO	Jan 06 '26	Sale	1.11	3,925	4,357	88,273	Jan 07 04:30 PM
Lettmann Jason	CHIEF EXECUTIVE OFFICER	Sep 17 '25	Buy	1.08	71,163	76,892	305,121	Sep 18 04:23 PM
Lettmann Jason	CHIEF EXECUTIVE OFFICER	Sep 16 '25	Buy	1.07	21,070	22,461	233,958	Sep 18 04:23 PM
Shantharam Harish	Chief Financial Officer	Aug 18 '25	Buy	0.78	75,000	58,402	75,000	Aug 20 04:02 PM
Pinto Shelly	SVP, FINANCE AND CAO	Aug 15 '25	Sale	0.64	611	391	89,198	Aug 19 04:12 PM
Lettmann Jason	CHIEF EXECUTIVE OFFICER	Aug 15 '25	Sale	0.64	2,382	1,525	212,888	Aug 19 04:09 PM
Pinto Shelly	SVP, FINANCE AND CAO	Jul 07 '25	Sale	0.45	2,011	905	86,809	Jul 08 04:37 PM
Pinto Shelly	SVP, FINANCE AND CAO	Jun 30 '25	Sale	0.43	1,532	659	88,820	Jul 01 04:22 PM
Pinto Shelly	SVP, FINANCE AND CAO	Feb 19 '25	Sale	1.15	550	633	87,352	Feb 21 04:25 PM
Pons Jaume	PRESIDENT & CSO	Feb 19 '25	Sale	1.15	1,326	1,525	579,388	Feb 21 04:23 PM
Lettmann Jason	CHIEF EXECUTIVE OFFICER	Feb 19 '25	Sale	1.15	2,159	2,483	170,270	Feb 21 04:20 PM

BIOA

BioAge Labs Inc

ALXO

Alx Oncology Holdings Inc

Upgrade your FINVIZ experience